Cancer charity recommends outcomes-based pricing in the UK

A new report from Cancer Research UK lends support to the use of outcomes-based pricing, stating that: “As well as providing value for money for the NHS [National Health Service], companies whose medicines represent genuine advances would also be rewarded.”

The charity says that innovative oncology products are often “complex and highly expensive, and in some cases the full extent of patient benefit may be unclear when evidence is still emerging.”

“This can make it difficult for the NHS and the drugs’ manufacturers to agree a price for them, resulting in delays,” the charity says.